Key Takeaways
- 1.3 ATA soft-shell chambers are FDA-cleared only for acute altitude sickness — all other use is off-label.
- At 1.3 ATA with 85–95% oxygen, dissolved plasma oxygen is substantially lower than at the clinical 2.0 ATA / 100% O₂ standard.
- The strongest neurological HBOT evidence (TBI, stroke, long COVID) uses 2.0 ATA — the Efrati Lab research pressure, not 1.3 ATA.
- Marketing claims for mild HBOT frequently exceed the published clinical evidence.
- Legitimate low-risk uses: altitude sickness (FDA-cleared), general wellness, access-constrained users who cannot reach clinical HBOT.
What 1.3 ATA Actually Is
Soft-shell portable chambers pressurise to approximately 1.3 atmospheres absolute (ATA) using ambient air with a supplemental oxygen concentrator feeding 85–95% O₂ into a mask or hood. This is distinct from clinical "medical HBOT," which uses hard-shell chambers at 2.0–3.0 ATA with 100% medical-grade oxygen.
FDA Status
The FDA has cleared 1.3 ATA soft-shell chambers for exactly one indication: acute mountain sickness. Any other use — TBI, long COVID, autism, recovery, wellness — is off-label, regardless of what marketing materials claim.
Pharmacokinetic Reality
At 1.3 ATA breathing ~95% oxygen, dissolved plasma oxygen is substantially lower than at the clinical 2.0 ATA / 100% O₂ standard. The physiological driver of HBOT efficacy — elevated arterial oxygen tension (PaO₂) — is weaker at 1.3 ATA. Whether this is enough to produce clinically meaningful effects for most indications remains debated.
What the Trial Evidence Shows
The most-cited 1.3 ATA trials come from Rossignol (autism) and Harch (veterans with post-concussion syndrome / PTSD). Both reported positive signals, but with methodological caveats — including the challenge of designing a true sham at 1.3 ATA (any pressurisation produces identifiable sensations). Larger follow-up trials have shown mixed results.
By contrast, the strongest HBOT evidence for neurological indications — Efrati-lab TBI, stroke, long COVID, and fibromyalgia trials — uses 2.0 ATA in hard-shell chambers with 100% oxygen. The pressure difference matters, both pharmacologically and in terms of effect sizes observed.
Legitimate Uses of 1.3 ATA
- Altitude sickness — the one FDA-cleared indication, with sound physiological rationale.
- General wellness use — low risk, modest expected benefit. Reasonable if the user understands the evidence base.
- Access to clinical-grade HBOT is impossible — some patients use 1.3 ATA home chambers because 2.0 ATA treatment is logistically or financially inaccessible.
Where 1.3 ATA Falls Short
- Not sufficient for UHMS-approved emergency indications (decompression sickness, CO poisoning, gas gangrene).
- Weaker evidence base than 2.0+ ATA for neurological indications.
- Marketing claims often outrun the clinical data.
Bottom Line
Mild HBOT at 1.3 ATA is not inherently fraudulent, but the marketing around it frequently overstates the evidence. For UHMS-approved indications and research-grade neurological protocols, hard-shell chambers at 2.0 ATA or higher remain the clinical standard. For wellness-level use, 1.3 ATA is a reasonable low-risk option with modest expected benefit.
Frequently Asked Questions
Is mild HBOT at 1.3 ATA worthless?
No — it has a legitimate FDA-cleared indication (altitude sickness) and may offer modest benefit for some wellness uses. The problem is marketing that overstates efficacy for conditions where the clinical evidence uses higher pressures.
Can 1.3 ATA treat TBI or long COVID?
Some positive signals exist at lower pressures, but the strongest RCT evidence for neurological HBOT uses 2.0 ATA. Pressure appears to matter for therapeutic effect.
Should I buy a soft-shell home chamber?
Depends on your goals. For altitude sickness or general wellness with realistic expectations, soft-shell is reasonable. For serious off-label indications (TBI, long COVID), consider that 2.0 ATA clinical HBOT has stronger evidence.
Is 1.3 ATA safer than clinical HBOT?
Marginally — lower barotrauma and oxygen toxicity risk. However, both pressures have excellent safety profiles. The practical safety difference is minor.
